MATClinics Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • MATClinics's estimated annual revenue is currently $10.4M per year.(i)
  • MATClinics's estimated revenue per employee is $216,000

Employee Data

  • MATClinics has 48 Employees.(i)
  • MATClinics grew their employee count by 14% last year.

MATClinics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M369%N/AN/A
#2
$160.7M47610%N/AN/A
#3
$8.6M4011%N/AN/A
#4
$17.3M7111%N/AN/A
#5
$28.4M1057%N/AN/A
#6
$10.2M479%N/AN/A
#7
$6.7M313%N/AN/A
#8
$34.3M127-8%N/AN/A
#9
$7.1M33-3%N/AN/A
#10
$6.7M313%N/AN/A
Add Company

What Is MATClinics?

MATClinics are dedicated to helping people recover from addiction to Opioids through access to Medication Assisted Treatment (MAT). Medication Assisted Treatment combines prescription medication with behavioral therapy to treat opioid addiction. MATClinics help patients overcome the physical, emotional and social barriers associated with recovery. Suboxone (and other (buprenorphine based medications) are proven to help patients addicted to Opioids. Patients replace their use of prescription medications or street drugs with daily doses of buprenorphine. The treatment regimen allows people to take their medication in the privacy of their own home and on a schedule that works for them. Most importantly, the treatment allows people to stop using prescription or street Opioids and avoid withdrawal symptoms and cravings. Unlike Methadone, patients on buprenorphine report feeling normal without any associated euphoria. The combination of medication treatments with counseling allows people to recover from their addiction and go back to living healthy and productive lives.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$10.4M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.4M480%N/A
#2
N/A48-16%N/A
#3
$6.9M48860%N/A
#4
$8.1M4812%N/A
#5
$4.6M48-6%N/A